Jefferson University Hospitals

Provider Profile

Serge A. Jabbour, MD, FACP, FACE

Jefferson University Physician

Academic Title: Professor
Division Director, Endocrinology
Director, Diabetes Center
Director, Comprehensive Weight Management Program

Endocrinology/Diabetes & Metabolism
Endocrinology/Diabetes & Metabolism - Thyroid & Parathyroid
Endocrinology/Diabetes & Metabolism - Weight Management

Appointment Scheduling

Call 1-800-JEFF-NOW

Existing Patients

Jefferson Health MyChart

Log in to MyChart and schedule an appointment online.

New Patients  | Online Scheduling

New patients can use Online Scheduling to view available appointment times and schedule directly.

More Ways to Get in Touch

Call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Walnut Towers, Suite 600
211 S. 9th Street
Philadelphia PA 19107
Phone: (215) 955-1925
Fax: (215) 928-3160

Medical Services

Years in Practice


Board Certifications

  • Internal Medicine
  • Endocrinology, Diabetes & Metabolism

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011


  • St. Joseph's University, Beirut, Lebanon, Medical School


  • Cooper Medical Center, Camden, NJ


  • Cooper Medical Center, Camden, NJ


  • Thomas Jefferson University Hospital

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • 1199
  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Devon
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Prime Health Services, Inc.
  • Qualcare
  • Teamsters Ins
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study

Serum Fructosamine: A Simple and Inexpensive Test for Assessing Preoperative Glycemic Control

Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial

Durability of response to dapagliflozin: a review of long-term efficacy and safety

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)

Diagnosis and management of thyroid lymphoma

Evaluation and management of medullary thyroid cancer

Insulin degludec 200 Units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 Units/mL in patients with type 2 diabetes requiring high-dose insulin

Musculoskeletal manifestations of primary hyperparathyroidism

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

SGLT2 inhibitors

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study

Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Incidence and Severity of Pancreatogenic Diabetes After Pancreatic Resection

Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem